* TG Therapeutics Inc reported quarterly adjusted earnings of 2 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 73 cents. The mean expectation of eight analysts for the quarter was for earnings of 3 cents per share. Wall Street expected results to range from -5 cents to 8 cents per share.
* Revenue fell 49.4% to $83.88 million from a year ago; analysts expected $81.71 million.
* TG Therapeutics Inc's reported EPS for the quarter was 2 cents.
* The company reported quarterly net income of $3.88 million.
* TG Therapeutics Inc shares had risen by 15.0% this quarter and gained 57.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 616.6% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for TG Therapeutics Inc is 41.50 This summary was machine generated from LSEG data November 4 at 03:20 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.03 0.02 Missed
Jun. 30 2024 -0.05 0.04 Beat
Dec. 31 2023 -0.04 -0.07 Missed
Dec. 31 2023 -0.10 -0.10 Met
Comments